Tyrosine Kinase Inhibitors

Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL

Medicosis Perfectionalis

HCC Whiteboard #2: The Mechanisms of Action of Tyrosine Kinase Inhibitors

Webinar Wednesdays - Tyrosine kinase inhibitors & PKD

Bruton Tyrosine Kinase Inhibitors

Immuno-oncology agents plus tyrosine kinase inhibitors?

HCC Whiteboard #3: The Management of Adverse Events of Tyrosine Kinase Inhibitors

The future of tyrosine kinase inhibitors for melanoma and open questions

Inhibition of ABL tyrosine kinases shows potential for metastatic cancer treatment

AJE Video Bytes

Use of VEGF-Targeted Tyrosine Kinase Inhibitors

Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCC

For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Selecting EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Lung Cancer

Targeted Oncology

Highlights From Bruton’s Tyrosine Kinase Inhibitors

Antibody Arrays to Assess resistance to Tyrosine kinase inhibitors | Protocol Preview

JoVE (Journal of Visualized Experiments)

Selecting a Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia Case Study

Short topics: Tyrosine kinase inhibitors

Clinical Pharmacology Lectures

Anti-PD1 or tyrosine kinase inhibitors?

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors. 02

Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc